ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report

A hematologic condition expressed as a lung disease

[version 1; peer review: 2 approved, 1 approved with reservations]
PUBLISHED 12 Oct 2012
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Pleural involvement secondary to Multiple Myeloma is considered a very rare complication. According to the literature only 1% of these patients develop a myelomatous pleural effusion. We present a case of a 39 year old man with multiple myeloma diagnosed six years prior to our evaluation, which developed progressive dyspnea, dry cough and right pleuritic chest pain two weeks prior to admission. On physical examination the patient had decreased breath sounds over the right posterior hemithorax accompanied by dullness to percussion. The chest radiogram was consistent with a right sided pleural effusion. Pleural fluid analysis revealed the presence of abundant abnormal plasma cells. The patient died four weeks after hospitalization. The presence of myelomatous pleural effusion is considered to be a poor prognostic finding, no matter at what disease stage it develops. So far no definite treatment has been shown to improve survival.

Introduction

Multiple Myeloma (MM) is a malignant neoplasm characterized by abnormal proliferation of plasma cells. The disease is typically manifested by anemia, pathologic fractures, hypercalcemia and renal failure. Pleural involvement in MM is very rare and seldom has been described in the literature. To our knowledge, approximately eighty cases have been mentioned in the largest case series reported. Pleural effusions can be either myelomatous or non-myelomatous, the former being the less common presentation. Most cases of myelomatous pleural effusions are due to IgA MM. We present a case of a patient with a pleural effusion secondary to IgG MM.

Case report

A 39 year old man with hypertension, end-stage renal disease and chronic smoker, diagnosed with MM six years prior to our evaluation, came to our institution complaining of progressive dyspnea, fever, and dry cough of two weeks of evolution. He was treated with a course of oral antibiotics for five days with minor symptom improvement. On admission the patient was found with a temperature of 37.8°C, heart rate was 118/min., respiratory rate was 24 breaths/min., blood pressure was 120/74 mmHg, and oxygen saturation by pulse oximetry was 100% with a venturi-mask at 50% FIO2. Chest examination revealed multiple bilateral palpable plasmacytomas along the anterior and posterior hemithorax with decreased breath sounds below the right scapular area, and percussion dullness was heard on the right side. Antero-posterior chest radiogram showed a large right side pleural effusion with contralateral shifting of the mediastinal structures and patchy airspace opacities throughout the left lung (Figure 1). Complete blood count revealed pancytopenia with a WBC of 2.8 × 109/l, Hb of 8.4 g/dl and platelet count of 19 × 109. Blood chemistry showed a protein of 5.6 g/dl and lactate dehydrogenase of 721 IU/l. Calcium levels were within normal limits. Diagnostic and therapeutic thoracentesis was performed after platelet transfusion and a total of 900 ml of turbid, sero-sanguinous fluid was removed. Pleural fluid analysis was consistent with an exudate and the fluid cytology revealed the presence of abundant atypical plasma cells (Figure 2). Bacteria, fungi and acid fast smear and cultures of the pleural fluid were reported negative. The patient’s clinical condition was aggravated by bacteremia, septic shock and respiratory failure requiring mechanical ventilation. The patient was complicated by sepsis and died four weeks after hospitalization.

cc93ed57-dfa4-4fd4-b279-e4038f666571_figure1.gif

Figure 1. Antero-posterior chest x-ray on admission showing right-sided pleural effusion.

cc93ed57-dfa4-4fd4-b279-e4038f666571_figure2.gif

Figure 2. Photomicrograph of pleural fluid showing atypical plasma cells (Giemsa stain x 400).

Discussion

Extra-medullary involvement in MM is considered to be a rare complication of the disease1. Commonly involved sites are the nasal cavity, lung, pleura, thoracic wall, central nervous system, lymph nodes, spleen, skin and eyes. Involvement of serous cavities such as the pleural cavity, peritoneal cavity, cerebral-spinal space and pericardium is unusual, the pleural cavity being the most common site2. Pleural effusions occur in 6% of the patients with multiple myeloma and can be myelomatous or non-myelomatous35. Non-myelomatous pleural effusions can occur secondary to sepsis, pulmonary embolism, chronic renal failure and secondary neoplasm6. On the other hand, myelomatous pleural effusions have been described in only in 1% of the patients with MM and the diagnosis is based on the demonstration of monoclonal proteins in the pleural fluid by protein electrophoresis, finding monoclonal plasma cells in the fluid and/or histological examination of the pleura through biopsy7,8. Literature reveals that almost 40% of the cases of myelomatous pleural effusions are due to IgG type6.

Multiple treatment regimens have been used including VAD regimen (vincristine, doxorubicin and dexamethasone), prednisolone, melphalan, etoposide, stem cell rescue and pleurodesis without a significant effect on mortality6,9. The use of bortezomib, a protease inhibitor, in refractory multiple myeloma has shown promising results. There is a single case of refractory MM and myelomatous pleural effusion treated successfully with intravenous and intrapleural bortezomib2,10.

Conclusion

There has been limited information in the literature regarding pulmonary manifestations of this hematologic malignancy. Pleural effusions can be present as an initial manifestation of the disease or as the disease progresses. As in our case, pleural involvement is associated with poor prognosis and high mortality rate no matter at what disease stage it appears. So far, there are no proven treatment regimens that can halt disease progression. Physicians should be aware of such a fatal complication as it predicts a very poor outcome. For this reason, additional studies towards the development of new treatment strategies should be considered.

Consent

Written informed consent for publication of clinical details and clinical images was obtained from the relative of the patient.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 12 Oct 2012
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Egozcue-Dionisi M, Nieves-Nieves J, Fernández-Gonzalez R et al. A hematologic condition expressed as a lung disease [version 1; peer review: 2 approved, 1 approved with reservations]. F1000Research 2012, 1:28 (https://doi.org/10.12688/f1000research.1-28.v1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 12 Oct 2012
Views
5
Cite
Reviewer Report 12 Nov 2012
Hermann Einsele, Department of Internal Medicine II, University of Wurzburg, Wurzburg, Germany 
Approved
VIEWS 5
The response quality following high‐dose chemotherapy and autologous stem cell transplantation for multiple myeloma (MM) is clearly correlated with progression‐free and probably also overall survival. Thus a major goal of all protocols for the treatment of younger patients with MM
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Einsele H. Reviewer Report For: A hematologic condition expressed as a lung disease [version 1; peer review: 2 approved, 1 approved with reservations]. F1000Research 2012, 1:28 (https://doi.org/10.5256/f1000research.201.r316)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
7
Cite
Reviewer Report 07 Nov 2012
Sarah Waheed, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA 
Approved with Reservations
VIEWS 7
The author has failed to mention if this patient had ever received any chemotherapy previously and if they did what agents were used. Also what was the initial presentation of myeloma in this patient?

The only imaging modality used was a
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Waheed S. Reviewer Report For: A hematologic condition expressed as a lung disease [version 1; peer review: 2 approved, 1 approved with reservations]. F1000Research 2012, 1:28 (https://doi.org/10.5256/f1000research.201.r315)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
4
Cite
Reviewer Report 30 Oct 2012
Artur Jurczyszyn, Department of Hematology, Jagiellonian University Medical College, Krakow, Poland 
Approved
VIEWS 4
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Jurczyszyn A. Reviewer Report For: A hematologic condition expressed as a lung disease [version 1; peer review: 2 approved, 1 approved with reservations]. F1000Research 2012, 1:28 (https://doi.org/10.5256/f1000research.201.r313)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 12 Oct 2012
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.